Abstract
Reagents such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), chlorpromazine, prenylamine, and N2-dansyl-L-arginine-4-t-butylpiperidine amide (No. 233) that interact with Ca2+-regu1ated modulator protein (modulator protein, calmodulin) were found to inhibit dose dependently not only Ca2+-dependent protein kinase (myosin light chain kinase), but also Ca2+-dependent ATPase of chicken gizzard actomyosin. Inhibition of Ca2+-dependent ATPase by these agents was prevented by the addition of modulator protein. These agents did not inhibit calcium-independent Mg2+-ATPase of actomyosin. Ca2+-dependent transfer of 32Pi from [γ-32P]ATP to the 20,000-dalton light chain of the gizzard myosin in the presence of Mg2+ was also inhibited dose dependently by these agents. The concentrations of these agents producing 50% inhibition of the Ca2+-dependent ATPase activity were found to be similar to concentrations producing 50% inhibition of myosin light chain phosphorylation, thereby suggesting that the inhibition of Ca2+-dependent ATPase of actomyosin by these drugs is due to their inhibition of myosin light chain phosphorylation. W-7 bound to Ca2+ modulator protein complex, but not to the modulator protein in the presence of EGTA. No. 233 and chlorpromazine inhibited the binding of W-7 to the Ca2+-modulator complex, suggesting that No. 233 and chlorpromazine bind to modulator protein. The modulator protein has two classes of W-7 binding sites: three functional sites with a high affinity for W-7 (KW-7 = 11 µM) and nine sites with a low affinity for the drug (KW-7 = 200 µM). W-7 did not show a significant binding to actin, myosin, tropomyosin, and bovine serum albumin at the concentration of the drug capable of binding to modulator protein. Troponin C was the only protein other than modulator protein that bound W-7 significantly but the affinity (KW-7 = 25 µM) of this protein for W-7 was lower than that of modulator protein. These results suggest that agents that interact with modulator protein produce relaxation of smooth muscle by inhibition of modulator protein-dependent myosin light chain phosphorylation thus suppressing the actin-myosin interaction and concomitant myosin ATPase activation.
ACKNOWLEDGMENTS We thank M. Ohara, Kyoto University for critical reading of the manuscript, and Dr. T. Totsuka for helpful discussion.
- Copyright © 1980 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|